Molecular Genetics of HSV DNA Polymerase Gene
HSV DNA聚合酶基因的分子遗传学
基本信息
- 批准号:8105921
- 负责人:
- 金额:$ 50.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-04-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcyclovirAddressAntiviral AgentsBase Excision RepairsBindingBiochemicalBiologicalBiological AssayBiologyCatalytic DomainCellsCytomegalovirusDNADNA BindingDNA biosynthesisDNA-Directed DNA PolymeraseDNA-Protein InteractionDevelopmentDiffuseDiffusionDiseaseDrug Delivery SystemsDrug resistanceEngineeringEnsureEnzymesExonucleaseFingersGanciclovirGenesGrantHealthHerpesviridaeHerpesviridae InfectionsHomologous GeneHumanHumulusImmunityLeadLearningLyaseMapsMethodsMolecularMolecular GeneticsMutationN-terminalPharmaceutical PreparationsPhosphodiesterase IPolymerasePolymerase GenePopulationPropertyProtein BindingProtein-Protein Interaction MapProteinsResearchResistanceRoleScreening procedureSideSimplexvirusSimplexvirus DNA polymeraseSlideStructureTechniquesThumb structureViralViral Drug ResistanceViral PhysiologyVirusVirus ReplicationWidespread DiseaseX-Ray Crystallographybasecombatdrug developmentdrug discoveryhigh throughput screeninghuman DNAimprovedin vivoinhibitor/antagonistinterdisciplinary approachinterestmouse modelmutantprototyperepair enzymeresistance mutationsingle moleculeuracil-DNA glycosylase
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this research is a detailed understanding of herpesvirus DNA polymerases and drugs that target them. These enzymes, which include a catalytic subunit (Pol) and an accessory subunit that stimulates long-chain DNA synthesis, are both prototype ?-like DNA polymerases and excellent targets for antiviral drugs. This latter property is especially health-related, as new drugs are needed for treatment of herpesvirus infections. In this application, unanswered questions regarding accessory subunits, catalytic subunits, and drugs that target these proteins and their interaction are addressed. Specific aim 1 is to investigate the unusual and different manners by which the accessory subunits, such as herpes simplex virus (HSV) UL42 and human cytomegalovirus (HCMV) UL44, interact with DNA so that they bind tightly, yet diffuse linearly along the DNA to permit processive DNA synthesis. Single-molecule approaches will be used to analyze how these proteins move on DNA, particularly whether wild type UL42 or a tight-binding mutant necessarily moves helically or can, for example, move along one side of the helix. The force required to move these subunits will be compared with the force required to stop or slow the catalytic subunits. X-ray crystallography will be used to understand the molecular details of the protein-DNA interaction. Specific aim 2 is to investigate the roles of structural domains of the catalytic subunits that are N-terminal to the thumb, palm, and fingers domains in terms of enzymatic functions, binding to the base excision repair (BER) enzyme uracil DNA glycosylase (UNG), viral replication, and mechanisms of antiviral drug resistance. Two structural domains, pre-NH2 and NH2, have been observed in the crystal structure of HSV Pol, but their roles in enzyme function and viral replication are unknown. To address these questions, mutant enzymes will be engineered and assayed for relevant biochemical activities. Mutant viruses will be engineered and assayed for viral replication both in cells and in a mouse model. The mechanisms by which mutant HCMV Pols with substitutions in their 3'-5' exonuclease domain resist ganciclovir (GCV) action will be investigated using enzymological analyses. Specific aim 3 is to discover new compounds that inhibit the interaction of HCMV Pol and UL44, and HCMV replication, using a structure-based approach. The importance of the interaction between UL44 and another replication protein, UL84, for viral replication, and whether it can be exploited as a drug target, will be investigated using a combination of biochemical, molecular genetic, and cell biological approaches, including efforts to develop a new technique to map protein-protein interactions. Should the UL44-UL84 interaction look promising as a drug target, random screening for compounds that inhibit this interaction will be undertaken.
PUBLIC HEALTH RELEVANCE: Herpesviruses cause widespread disease in the population at large and severe disease in people with impaired immunity. There is considerable need for new drugs to combat these viruses. The research proposed should not only provide information that could aid in drug discovery and understanding how viruses become resistant to current drugs, but aims directly to discover new anti-herpesvirus drugs.
描述(由申请人提供):这项研究的长期目标是详细了解疱疹病毒DNA聚合酶和针对它们的药物。这些酶包括一个催化亚基(POL)和一个辅助亚基,刺激长链DNA合成,都是原型?DNA聚合酶,也是抗病毒药物的优秀靶点。后一种特性尤其与健康有关,因为治疗疱疹病毒感染需要新药。在本应用中,针对这些蛋白质及其相互作用的辅助亚基、催化亚基和药物的未回答问题被解决。具体目的1是研究单纯疱疹病毒(HSV)UL42和人巨细胞病毒(HCMV)UL44等辅助亚基与DNA相互作用的不同方式,使它们紧密结合,但又沿DNA线性扩散,从而允许DNA合成。单分子方法将被用来分析这些蛋白质如何在DNA上移动,特别是野生型UL42或紧密结合的突变体是否必然螺旋移动,或者例如,可以沿着螺旋的一侧移动。移动这些亚基所需的力将与停止或减缓催化亚基所需的力进行比较。X射线结晶学将被用来了解蛋白质-DNA相互作用的分子细节。具体目的2是从酶功能、与碱基切除修复(BER)酶尿嘧啶DNA糖基酶(UNG)的结合、病毒复制和抗病毒耐药机制等方面,研究拇指、手掌和手指结构域的催化亚基的结构域的作用。在HSV Pol的晶体结构中观察到两个结构域,即Pre-NH2和NH2,但它们在酶功能和病毒复制中的作用尚不清楚。为了解决这些问题,将设计突变酶并对其进行相关的生化活性检测。突变病毒将被设计并检测病毒在细胞和小鼠模型中的复制。用酶学方法研究突变株HCMV POLS在3‘-5’外切酶结构域上抵抗更昔洛韦(GCV)作用的机制。具体目标3是使用基于结构的方法发现抑制HCMV Pol和UL44相互作用以及抑制HCMV复制的新化合物。UL44和另一种复制蛋白UL84之间的相互作用对病毒复制的重要性,以及它是否可以被用作药物靶点,将结合生化、分子遗传学和细胞生物学方法进行研究,包括努力开发一种新的技术来绘制蛋白质-蛋白质相互作用图。如果UL44-UL84相互作用看起来有希望成为药物靶点,将随机筛选抑制这种相互作用的化合物。
公共卫生相关性:疱疹病毒在一般人群中引起广泛疾病,在免疫力受损的人中引起严重疾病。对抗这些病毒的新药有相当大的需求。拟议的研究不仅应该提供有助于药物发现和了解病毒如何对现有药物产生抗药性的信息,而且直接旨在发现新的抗疱疹病毒药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DONALD M COEN其他文献
DONALD M COEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DONALD M COEN', 18)}}的其他基金
Antagonizing miRNAs in a strategy to cure HSV latency
拮抗 miRNA 来治愈 HSV 潜伏期
- 批准号:
8510128 - 财政年份:2013
- 资助金额:
$ 50.74万 - 项目类别:
Viral And host mechanisms that tilt the HSV lytic/latent balance
导致 HSV 裂解/潜伏平衡倾斜的病毒和宿主机制
- 批准号:
8871671 - 财政年份:2013
- 资助金额:
$ 50.74万 - 项目类别:
Project 2 - Post-transcriptional mechanisms and the HSV lytic/latent balance
项目 2 - 转录后机制和 HSV 裂解/潜伏平衡
- 批准号:
10226131 - 财政年份:2013
- 资助金额:
$ 50.74万 - 项目类别:
VIral and host mechanisms that tilt the HSV lytic/latent balance
导致 HSV 裂解/潜伏平衡倾斜的病毒和宿主机制
- 批准号:
9791972 - 财政年份:2013
- 资助金额:
$ 50.74万 - 项目类别:
Project 2 - Post-transcriptional mechanisms and the HSV lytic/latent balance
项目 2 - 转录后机制和 HSV 裂解/潜伏平衡
- 批准号:
9791977 - 财政年份:2013
- 资助金额:
$ 50.74万 - 项目类别:
VIral and host mechanisms that tilt the HSV lytic/latent balance
导致 HSV 裂解/潜伏平衡倾斜的病毒和宿主机制
- 批准号:
10460505 - 财政年份:2013
- 资助金额:
$ 50.74万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 50.74万 - 项目类别:
Research Grant














{{item.name}}会员




